SCHEMBL692774

SCHEMBL692774

CCN(Cc1ccccc1)c1ccc(-c2cccc(NS(=O)(=O)C(F)(F)F)c2)nn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
ENPP2 Q13822 1/20 0.40
TP53 P04637 4/20 0.39
MAPT P10636 3/20 0.39
LMNA P02545 4/20 0.39
POLB P06746 1/20 0.39
KDM1A O60341 1/20 0.38
ALDH1A1 P00352 2/20 0.38
THRB P10828 2/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL692966 0.88 NR3C1 (0.56) NR3C1TP53LMNAPOLBALDH1A1
SCHEMBL692379 0.86 PRMT6 (0.43) NR3C1PRMT6ENPP2TP53MAPT
SCHEMBL692541 0.83 NPC1 (0.53) TP53MAPTLMNAPOLBALDH1A1
SCHEMBL692595 0.81 TP53 (0.45) TP53MAPTLMNAPOLBALDH1A1
SCHEMBL7710033 0.80 ENPP2 (0.38) NR3C1ENPP2TP53MAPTNPC1
SCHEMBL7898157 0.76 NR3C1 (0.43) NR3C1PRMT6KDM1APTGS1PTGS2
SCHEMBL1369219 0.75 ENPP2 (0.42) ENPP2TP53MAPTLMNAALDH1A1
SCHEMBL3507875 0.71 CA2 (0.54) NR3C1PRMT6LMNAKDM1AALDH1A1
SCHEMBL3242528 0.69 ENPP2 (0.45) ENPP2TP53NPC1RAB9A
SCHEMBL10299432 0.68 NR3C1 (0.43) NR3C1MAPTLMNAALDH1A1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560654-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2013-02-27 EP claimed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US claimed
EP-2421368-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2012-02-29 EP claimed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US claimed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO claimed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO claimed
EP-2560654-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2013-02-27 EP disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
EP-2421368-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2012-02-29 EP disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO disclosed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES CFTR, PKD1, PKD2 NR3C1 3998/4885PRMT6 4112/4885ENPP2 825/4885
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives SCN1A, CLIC1, CLCN2 NR3C1 3488/4885PRMT6 4209/4885ENPP2 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.